Highlights Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets Other stock markets 03:59:59 2024-07-12 pm EDT			5-day change	1st Jan Change
10.46 ^USD	+1.26%		+4.39%	-12.10%

Jul. 02	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
Jun. 03	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	Jul. 01	CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	Jun. 02	MT
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	May. 21	CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16	DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	May. 08	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	Apr. 25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	Apr. 25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17	RE
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Highlights

Filters